Table 1 Panellists experience on ICS withdrawal in COPD patients.

From: Investigating the rationale for COPD maintenance therapy prescription across Europe, findings from a multi-country study

   

Results by specialty

  

Total sample

General practitioners

Pulmonologists

p value

Patients’ distribution per panellist, in the last year

N respondents

127

45

82

 

Total COPD patients seen in the last year, mean

 

300

97

410

<0.0001

ICS-treated patients, N (%)

 

117 (37.1%)

29 (28.2%)

165 (42.0%)

<0.0001

ICS-treated patients eligible for ICS withdrawal, %

 

22.0%

24.9%

20.4%

<0.0001

Have you ever withdrawn ICS treatment from any COPD patient? Yes, n (%)

 

119 (93.7)

40 (88.9)

79 (96.3)

0.098

Patients withdrawn from ICS treatment, %

 

17.2%

14.5%

18.5%

0.207

Patients that refused ICS withdrawal, %

 

8.6%

11.1%

7.4%

0.251

Patients distribution per panellist (only those who have withdrawn an ICS treatment in the last year)

N respondents

111

34

76

 

Reason for ICS withdrawal, %

 No longer indication for ICS

 

49.5%

49.2%

49.6%

0.956

 Lack of response to ICS

 

27.1%

27.4%

26.9%

0.935

 Pneumonia

 

11.8%

12.2%

11.6%

0.880

 Fear of adverse events to ICS

 

11.2%

11.2%

11.3%

0.979

 Other

 

0.5%

0.0%

0.7%

0.256

Outcome of ICS withdrawal, %

 Remained with no exacerbations within 6 months after ICS withdrawal

 

75.0%

77.0%

74.0%

0.500

 Needed ICS treatment reintroduction within 6 months after ICS withdrawal

 

16.0%

12.0%

18.0%

0.069

 Reasons for ICS re-introduction (only among those who needed a re-introduction), %

N respondents

81

19

62

 

Patient preference

 

16.0%

28.0%

12.0%

0.010

Increased symptoms

 

37.0%

35.0%

37.0%

0.762

Exacerbation

 

42.0%

37.0%

44.0%

0.387

Other

 

5.0%

0.0%

6.0%

0.166

  1. p values refer to the differences between specialties for each statement. Statistically significant differences were considered when p value <0.05.
  2. ICS inhaled corticosteroids, COPD chronic obstructive pulmonary disease.